NKX019
Phase 2Cell therapy
NKX019 is one of 129 biologic programs targeting Systemic Sclerosis. It is currently in Phase 2.
4
Indications
4
Total Trials
4
Active Trials
128
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
134 competitors in Systemic Lupus Erythematosus
#DrugCompanyPhaseTrials
1Rituxan
RochePhase 3
Medrol
PfizerPhase 3
Rinvoq
AbbViePhase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Gazyva
RochePhase 3
Sotyktu
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Rapamune
PPrism Pharmaceuticals
Phase 3
Ianalumab
NovartisPhase 3
Fludara
SanofiPhase 2
Glucocorticoid
AbbViePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Natural Killer Cell1 trial
Systemic Sclerosis1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for NKX019. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Highest Phase
- Phase 2[1]
- Company
- NNkarta, Inc.